Healthcare Industry News: Bladder Cancer
News Release - February 18, 2010
BSD Medical Announces First Swiss Installation of the BSD-2000/3D Hyperthermia System at Kantonsspital AarauSALT LAKE CITY--(HSMN NewsFeed)--BSD Medical Corporation (NASDAQ: BSDM ) announces the installation of the advanced BSD-2000/3D Hyperthermia System at the Department of Radiation Oncology of Kantonsspital Aarau (KSA), Aarau, Switzerland. The BSD-2000/3D at KSA will be used to deliver targeted hyperthermia to deep pelvic and abdominal tumors, using focused phased array RF energy, in order to enhance treatment with radiotherapy and chemotherapy. The purchase of the BSD-2000/3D adds sophisticated technology to KSA’s hyperthermia cancer therapy program. KSA had already joined BSD’s family of customers with the purchase of a BSD-500 superficial hyperthermia system.
“This new technology, when coupled with radiation and/or chemotherapy, gives us a new weapon against deep seated tumors such as Bladder Cancer, recurrent rectal cancer, prostate cancer and soft tissue sarcomas,” said Stefan Bodis MD, head of the Department of Radiation Oncology at KSA and Associate Professor of Radiotherapy at the University Medical School of Zurich, Zurich, Switzerland. Patient treatments in the new hyperthermia facility will start in April 2010.
The Department of Radiation Oncology of KSA delivers more than 20,000 radiation therapy sessions per year and is one of the most important radiation treatment centers in Switzerland. The Department of Radiation Oncology of KSA is a member of the Radiation Therapy Oncology Group (RTOG), which is a dynamic, multidisciplinary group of physicians and researchers from over 300 leading medical facilities in the United States, Canada and international countries. The Department of Radiation Oncology of KSA is also affiliated with MD Anderson Tumor Center in Houston and cooperates with MD Anderson on clinical studies and tutorials.
In the future, the BSD-2000/3D at KSA will be used also in conjunction with proton therapy delivered at the Paul Scherrer Institute (PSI), Center for Proton Radiation Therapy, Villigen, Switzerland. The Department of Radiation Oncology of Kantonsspital Aarau cooperates closely with the Paul Scherrer Institute, and the government of the Kanton Aarau has supported PSI with an grant of $20 million. PSI has developed a special proton radiation technique (spot-scanning procedure) for the treatment of deep-seated tumors. Proton therapy is a precise form of radiation therapy that minimizes damage to healthy tissue and surrounding organs. The spot-scanning procedure is a sophisticated method that allows the physician to precisely deliver maximum radiation therapy to a specific location within a tumor. More than 500 cancer patients have already received positive results from this treatment. The combination of hyperthermia and proton therapy will make it possible to treat patients who have very large, complex tumors and few, if any, available treatment options.
About BSD Medical Corporation
BSD Medical Corporation is a leading developer of systems used to deliver precision-focused microwave/RF energy to diseased sites in the body, including cancer. Its treatments are used to kill cancer directly and increase the effectiveness of companion radiation treatments for certain tumors. The BSD-2000 is restricted to investigational use in the United States. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
Source: BSD Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.